Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 15.76M +107.3% |
| Revenue (ttm) | n/a |
| Net Income | -57.80M |
| EPS | -22.01 |
| Shares Out | 2.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,700 |
| Open | 6.06 |
| Previous Close | 6.00 |
| Day's Range | 5.87 - 6.11 |
| 52-Week Range | 1.31 - 10.75 |
| Beta | 1.39 |
| Analysts | Buy |
| Price Target | 8.33 (+38.83%) |
| Earnings Date | Aug 14, 2026 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ADIL stock is "Buy." The 12-month stock price target is $8.33, which is an increase of 38.83% from the latest price.
News
Adial Pharmaceuticals files to sell 25.15M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 25.15M shares of common stock. The company is not selling any…
Adial Pharmaceuticals Registration statement: Registration filing
Adial Pharmaceuticals filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new emp...
Adial Pharmaceuticals Proxy statement: Proxy filing
Adial Pharmaceuticals filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline
Adial Pharmaceuticals Quarterly report: Q2 2026
Adial Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 17, 2026.
Adial Pharmaceuticals Earnings release: Q2 2026
Adial Pharmaceuticals released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Adial Pharmaceuticals Proxy statement: Proxy filing
Adial Pharmaceuticals filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Adial Pharmaceuticals initiated with a Buy at Alliance Global
Alliance Global analyst James Molloy initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $11 price target The firm sum-of-the-parts analyst assigns $9 per share in value for…
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Director...
Adial Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $6 price target The firm says the company’s newly acquired lead program is AT177 is a proprietary…
Adial Pharmaceuticals Slides: Investor presentation
Adial Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Adial Pharmaceuticals Transcript: M&A announcement
The acquisition brings a novel, colon-targeted therapy for ulcerative colitis and up to $64M in financing, with Azora equity holders gaining majority ownership. The combined company will focus on advancing AT177 through early clinical milestones.
Adial Pharmaceuticals Press release: M&A announcement
Adial Pharmaceuticals issued a press release on June 11, 2026, disclosing material business information to investors.
Adial Pharmaceuticals announces acquisition of Azora Therapeutics
Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a pr...
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mi...
Adial Pharmaceuticals Slides: Corporate presentation
Adial Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...
Adial Pharmaceuticals Quarterly report: Q1 2026
Adial Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
Adial Pharmaceuticals Earnings release: Q1 2026
Adial Pharmaceuticals released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Adial Pharmaceuticals files AD04 utility application with USPTO
Adial Pharmaceuticals (ADIL) announced the filing of a new U.S. utility application with the United States Patent and Trade Office, or USPTO, directed to AD04, the company’s lead investigational genet...
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility...
Adial submits AD04 product application for FDA CNPV pilot program
Adial Pharmaceuticals (ADIL) announced the submission of the AD04 product application for consideration of the FDA Commissioner’s National Priority Voucher Pilot Program. Announced in 2025, the CNPV p...
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatme...
Adial Pharmaceuticals completes AD04 demonstration batch production
Adial Pharmaceuticals (ADIL) announced completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for th...